SIGN-UP NOW! Click to become a Member for Free!









C. diff. Spores and More Tuesday at 10 AM Pacific December 3rd 2019: C. diff. Treatment Option;

**Oral Vancomycin Solution** 

Join Us with guest: Karl Kappeler, MS, RPh, FASHP Director, Medical Affairs of Azurity Pharmaceuticals. and will be discussing C. difficile infections, C. diff. treatment options and the Azurity Pharmaceuticals organization with its FDA approved product. Listen in as we learn more about the Company's history, their unique product offerings that help pharmacists compound drugs, and product information for FIRVANQ, their FDA approved vancomycin oral solution.

#### Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

#### LISTEN LIVE

EPISODE ON DEMAND

#### **VIEW HOST PAGE**

Questions? Comments? Call In Live! Call-In Toll Free: 1-866-472-5792 Intl: 001-480-553-5759





#### **Featured Guest**



#### Karl Kappele

Mr. Kappeler, Director, Medical Affairs, joined Azurity Pharmaceuticals through the acquisition of Silvergate Pharmaceuticals by CutisPharma in May 2019, forming the new company Azurity. Prior to the acquisition, Mr. Kappeler served as Director, Clinical Information at Silvergate Pharmaceuticals. Prior to joining Silvergate,

Read more

## **Share This Episode**







### Connect with VoiceAmerica

# Download our mobile apps

















Read what our hosts are writing about.

